TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Apparent terminal half-life (t1/2) of LC350189 and Colchicine from plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detrusor Leak Point Pressure (LPP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Security in the use of supraglottic devices
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax of safinamide in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: AUC0-∞ of safinamide in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Duration of aplasia period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerance of SeeMore
Endpoint domain: Adverse events/effects
Primary endpoint: Depth of focused thermal injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thermal injury zone dimensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parent-Adolescent Communication Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensitivity of central vein sign on MRI for diagnosing MS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vascular Endothelial Growth Factor Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Self-reported non-adherence to immunosuppressive medication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline to Week 24 in Body Mass Index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline to Week 24 in Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline to Week 24 in Fat Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CO2 extraction in blood samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Frequency and intensity of drinking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Evidence of allergic reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Fidelity/Adherence Via Subject Diary
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fluorescein corneal staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom Assessment in Dry Eye (SANDE) I and II questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Ventilator Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Samples Collected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time of pronuclei disappearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Two discrete cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morula stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-segment diameter stenosis (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum sodium nadir concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days with serum sodium concentration below 136mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days with serum sodium concentration below 133mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Migraine Disability Assessment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Incidence of severe unacceptable local adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Plasma Concentration-Time Curve (AUC0-12h) of Tazemetostat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Tazemetostat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance of ketogenic diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Incidence of Anti-pegfilgrastim Antibodies
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma oxyphytosterol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of no progression at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of combined antibiotics treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major adverse cardiac event (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak plasma concentration (Cmax) of metoprolol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of metoprolol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mother's risk for maltreating her child
Endpoint domain: Adverse events/effects
Primary endpoint: Mother's affective and instrumental parenting
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mother's psychosocial adjustment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: negative symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Neurobehavior evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative EEG (qEEG) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants Successfully Able to Insert Catheter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Accuracy of respiratory rate measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: stem cell mobilization (CD34, CD117, CD133, CXCR4+, C-met)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of ACPE recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Perceived treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma donor-derived cell-free DNA (dd-cfDNA) for routine surveillance of acute rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Allograft educated platelet-derived mRNA for gene expression profiling of acute rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma extracellular vesicle (EV) derived mRNA for gene expression profiling of acute rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma glycoproteins for routine surveillance of acute rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants experiencing serious device-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: reduction in the number of antiglaucoma medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Quality of Upper Extremities Skills Test (QUEST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Detection of chlorhexidine in tracheal secretions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of Occurrence of Cmax (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immediate postural control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Symptom Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative pain assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subject Composite Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Titer of the Meningococcal B Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentages of Participants With Serum Bactericidal Activity of the Meningococcal B Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titer of the Meningococcal ACWY Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Serum Bactericidal Activity of the Meningococcal ACWY Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects Who Reported Solicited Local and Systemic Reactions Post Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change in Daily Reflective Total Nasal Symptom Score (rTNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge and use of diagnostic tools and treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Model-Based Geometric Mean Ratio of 24-hour Objective Coughs Per Hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing At Least One Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Discontinued Treatment Due to AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in 25-hydroxyvitamin D Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Supplemental Opioid Use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: SERT and DAT occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Time a Patient is Able to Tolerate Wean
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coordination Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower Extremity Functional Performance Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline (CFB) in National Institutes of Health Stroke Scale (NIH-SS) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Vital Sign Parameter: Blood Pressure - SBP and DBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Response as assessed by RECIST criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improvement in Bone Mineral Density (BMD) of Spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: myocardial inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Radiographic Progression-free Survival (rPFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score of MATRICS Consensus Cognitive Battery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Positive And Negative Symptoms Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasmatic concentrations of sevoflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in serum HCV RNA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events (AEs) greater than or equal to grade 3
Endpoint domain: Adverse events/effects
Primary endpoint: Perceived Stress (PS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants with seroprotective antibody titres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline blood oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Hospital stay days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of ICU stay days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of intubation events
Endpoint domain: Adverse events/effects
Primary endpoint: Aortic valve area index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Radiographic findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Depression Rating Scale (HAM-D-17) Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in HCV RNA Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequate control of Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Renographic glomerular filtration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Red Blood Cell Transfusions Needed to Maintain Hemoglobin Levels (Short Term)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Platelet Transfusions Needed to Maintain Adequate Number of Platelets (Short Term)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total Number of Days of Stem Cell Collection (Short Term)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Quality of life (prostate-associated)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: sperm concentration in ejaculate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Spermatozoa in testicular biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in Exercise Capacity - Maximum Walking Time Reached
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child Posttraumatic Cognitions Inventory (CPTCI)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Overall Remission Rate (ORR) Per Independent Review Committee (IRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall Remission Rate (ORR) Per Local Investigator Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: FEV1 AUC (0-12h) Change From Patient Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Participant Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Participant Hypotension
Endpoint domain: Adverse events/effects
Primary endpoint: Patients-reported outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants not requiring treatment discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Eczema Area and Severity Index (EASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pattern of Abdominal Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: trabecular volume (bone volume / tissue volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Asian Pacific Colorectal Screening (APCS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of vascular structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Assessment of lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Assessment of fascia of Fredet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psoriasis improvement or worsening
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Brain Metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in duty cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in gate width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the length of end expiration or end inspiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Patients With Acute Respiratory Infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sensitivity and specificity of EIS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change of Haemodynamic Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rituximab response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Neck Pain Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in urinary pesticides levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in urinary polyphenol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in gut microbiome composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Induction of clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of target lesion revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cerebral tissue oxygen saturation (StO2) after birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral vaso-reactivity to arterial carbon dioxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in lipids and non-cholesterol sterols concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: suicide and accidental deaths
Endpoint domain: Mortality/survival
Primary endpoint: Feasibility of Pacemaker Implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Health related Quality of Life (HRQoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clinical Global Improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: monocular Corrected Distance Visual Acuity (CDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction of day case surgery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of 18F-BMS-986229 PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active management of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence rate to daily acupuncture
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Compliance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean daytime ambulatory systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Development of Bronchopulmonary Dysplasia (BPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of days spent logging headache data
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of days spent doing PMR
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Minutes/day spent doing PMR
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Positive predictive values of device detected atrial arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Expression of 15-PGDH mRNA and protein levels in tumor tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Expression of 15-PGDH mRNA and protein levels in normal colorectal mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Grade 3 and 4 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Achieve Sustained Virologic Response (SVR) 12 Weeks After Completion of Therapy (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uteroplacental Perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission rate of insomnia
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Periodontal Probing Depths (PD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Bleeding on Probing (BOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Radiographic Bone Fill (RBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with CAR-BCMA T cell therapy-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in plasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes